Publication: 2702

Publication: 2702

Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Clin Cancer Res vol 23 (22) 6802-6811

Year:: 2017
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 6

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:
Grants:: U10CA032291, U10CA077651, U10CA007968, U10CA180791, U10CA180867, 5UO1CA157703, 3U10CA180821-03S3, PC121341, U01 CA157703, U10 CA077202, U10 CA031946, U10 CA180821, U10 CA180863

Corr. Author:
Authors:: Himisha Beltran Alexander W Wyatt Edmund C Chedgy Adam Donoghue Matti Annala Evan W Warner Kevin Beja Michael Sigouros Fan Mo Ladan Fazli Colin C Collins James Eastham Michael Morris Mary-Ellen Taplin Andrea Sboner Susan Halabi Martin E Gleave

Networks:: LAPS-MA036, LAPS-MD017, LAPS-NY016

Study: CALGB-90203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: high-risk prostate cancer, neoadjuvant, docetaxel, ADT, genomics, integrative molecular analysis